Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232917 | 0.92 | CHEK1 (0.57) | RORCSMN1; SMN2RAB9AHTTPKM | |
| SCHEMBL12114840 | 0.90 | RORC (0.54) | RORCSMN1; SMN2RAB9AHTTPKM | |
| SCHEMBL6716569 | 0.88 | ANO1 (0.50) | RORCSMN1; SMN2RAB9AHTTPKM | |
| SCHEMBL6716574 | 0.88 | ANO1 (0.50) | RORCSMN1; SMN2RAB9AHTTPKM | |
| SCHEMBL7225723 | 0.88 | CHEK1 (0.60) | RORCSMN1; SMN2RAB9AKMT2AMAPT | |
| SCHEMBL6716577 | 0.87 | HTT (0.46) | RORCSMN1; SMN2HTTPKMKMT2A | |
| SCHEMBL9068677 | 0.84 | ALDH1A1 (0.54) | SMN1; SMN2HTTPKMKMT2AMAPT | |
| SCHEMBL6650235 | 0.84 | RORC (0.46) | RORCSMN1; SMN2HTTPKMKMT2A | |
| SCHEMBL6650250 | 0.82 | CTSV (0.52) | SMN1; SMN2RAB9AHTTPKMKMT2A | |
| SCHEMBL6651351 | 0.82 | LMNA (0.52) | RORCSMN1; SMN2HTTPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | ABBVIE INC. | 2003-04-10 | — | — | US | claimed |
| US-6518430-B1 | The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | claimed |
| US-20220280661-A1 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2021118728-A2 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021118728-A2 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-6673930-B2 | PREPARING A SELECTIVE GLUCOCORTICOID RECEPTOR AGENTS BY CYCLIZATION, DEHALOGENATION, AMINATION, ETHERIFICATION, HYDROXYLATION | ABBVIE INC. | 2004-01-06 | — | — | US | disclosed |
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | ABBVIE INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003027117-A1 | A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF | ABBOTT LABORATORIES (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6518430-B1 | The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6329534-B1 | USEFUL FOR THERAPY OF TYPE II DIABETES, OBESITY, HYPERGLYCEMIA, INADEQUATE GLUCOSE CLEARANCE, HYPERINSULINEMIA, HYPERTRIGLYCERIDEMIA, AND HIGH-CIRCULATING GLUCOCORTICOID LEVELS | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | RORC 519/4885SMN1; SMN2 4480/4885RAB9A 4602/4885 |
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | HTR3C, CYP3A5, NQO2 | RORC 1836/4885SMN1; SMN2 1849/4885RAB9A 2023/4885 |
| US-20220280661-A1 | GLUCOCORTICOID RECEPTOR RADIOLIGANDS AND METHODS FOR THEIR PREPARATION AND USE | NR3C1, NR3C2, MC2R | RORC 187/4885SMN1; SMN2 4823/4885RAB9A 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.